Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.
Understanding the Potential Risks of Prescription Drug Affordability Boards and Upper Payment Limits
A UPL is the maximum reimbursement certain payers can provide pharmacies and providers for a drug. A UPL caps what a payer ...
Admilparant 60 mg met the ALOFT-IPF primary end point, significantly improving FVC change vs placebo at 52 weeks in ...
Nogapendekin alfa inbakicept-pmln (Anktiva; ImmunityBio Inc) given with Bacillus Calmette-Guérin (BCG) is now the first ...
Dyshidrotic eczema behaves differently from other forms of hand eczema in ways that matter for how it is worked up and ...
Cancer survivors are living longer, but longer survival brings a new pressing question: who helps them live well afterward?
Iberdomide (Zenbexus; Bristol Myers Squibb) in combination with daratumumab and dexamethasone (ZDd) demonstrated a statistically significant improvement in the dual-primary end po ...
Postpartum navigation missed its primary goal but raised postpartum visits and primary care use among Medicaid-insured ...
When Erica Plybeah launched MedHaul in 2017, she didn’t just think medical transportation was a barrier to care. She’d lived ...
Population Health, Equity & Outcomes is a quarterly publication dedicated to providing a platform for the exchange of research, policy analysis, and insights that aim to improve health outcomes and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results